---
title: Molecular assessment of intratumoral immune cell subsets and potential mechanisms
  of resistance to odronextamab, a CD20CD3 bispecific antibody, in patients with relapsed/refractory
  B-cell non-Hodgkin lymphoma
date: '2024-03-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38519055/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240323180616&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: This biomarker analysis expands on clinical findings of
  odronextamab in patients with R/R B-NHL, providing verification of the suitability
  of CD20 as a therapeutic target, as well as evidence for potential mechanisms of
  action and ...'
disable_comments: true
---
CONCLUSIONS: This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and ...